



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 17:44  
**Last Report Issued** 05/13/2019 08:06

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 2538B  
**Patient ID** 2538B  
**Chain** 18001907  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 18001907  
**Received** 11/21/2018

**Lab ID** 18001907-001  
**Matrix** Blood  
**Patient Name** 2538B  
**Patient ID** 2538B  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2538B Loxapine, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Loxapine	None Detected	ng/mL	5.0	
Synonym(s): Adasuve®				

With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes. The blood to plasma ratio is not known.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.